Phase 1
Completed N=8
Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects
Source: ClinicalTrials.gov NCT04756960 ↗Enrolled (actual)
8
Serious AEs
0.0%
Results posted
Mar 2024
Primary outcomePrimary: PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total — 5.4025 h*ngEq/mL
Summary
The objective of the study is to evaluate the bioavailability of CHF6001 after inhaled administration, to characterize the mass balance and route of elimination of CHF6001 along with its relevant metabolites, in healthy male subjects.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total |
5.4025 | — |
| PRIMARY PK Parameter -- C(max_iv) -- Plasma -- [14^C] Total |
0.7072 | — |
| PRIMARY PK Parameter -- t(max_iv) -- Plasma -- [14^C] Total |
0.217 | — |
| PRIMARY PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] Total |
6.0825 | — |
| PRIMARY PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] Total |
72.4057 | — |
| PRIMARY PK Parameter -- (Blood to Plasma Ratio) -- Blood, Plasma -- [14^C] Total |
0.6490 | — |
| PRIMARY PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] CHF6001 |
0.7825 | — |
| PRIMARY PK Parameter -- C(max_iv) -- Plasma -- [14^C] CHF6001 |
0.6312 | — |
| PRIMARY PK Parameter -- t(max_iv) -- Plasma -- [14^C] CHF6001 |
0.217 | — |
| PRIMARY PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] CHF6001 |
0.8138 | — |
| PRIMARY PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] CHF6001 |
13.5816 | — |
| PRIMARY PK Parameter -- Volume of Distribution During the Terminal Phase (Vz_iv) -- Plasma -- [14^C] CHF6001 |
436.1078 | — |
| PRIMARY PK Parameter -- Vdss_iv -- Plasma -- [14^C] CHF6001 |
201.2514 | — |
| PRIMARY PK Parameter -- Clearance (CL_iv) -- Plasma -- [14^C] CHF6001 |
21.9951 | — |
| PRIMARY PK Parameter -- Blood to Plasma Ratio -- Blood, Plasma -- [14^C] CHF6001 |
0.5166 | — |
| PRIMARY PK Parameter -- AUC(0-t)_inh -- Plasma -- CHF6001 |
71088 | — |
| PRIMARY PK Parameter -- C(max_inh) -- Plasma -- CHF6001 |
1979 | — |
| PRIMARY PK Parameter -- t(max_inh) -- Plasma -- CHF6001 |
2.008 | — |
| PRIMARY PK Parameter -- AUC(0-∞_inh) -- Plasma -- CHF6001 |
72403 | — |
| PRIMARY PK Parameter -- t(1/2_inh) -- Plasma -- CHF6001 |
41.5691 | — |
| PRIMARY PK Parameter -- Absolute Inhaled Bioavailability (F_inh) -- Plasma -- CHF6001 |
0.4977 | — |
| PRIMARY PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C] Total |
1.99; 3.26; 3.93; 5.24; 6.77; 7.35 | — |
| PRIMARY PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C]-CHF6001 |
0.00; 0.00; 0.00; 0.00; 0.00; 0.00 | — |
| PRIMARY PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C] Total |
7.64; 38.9; 57.7; 64.9; 68.6; 69.6 | — |
| PRIMARY PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C]-CHF6001 |
0.0435; 0.1748; 0.2507; 0.2816; 0.3048; 0.3060 | — |
| PRIMARY PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C] Total |
1.99; 3.26; 3.93; 12.9; 45.6; 65.1 | — |
| PRIMARY PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C]-CHF6001 |
0.0435; 0.1748; 0.2507; 0.2816; 0.3048; 0.3060 | — |
Eligibility Criteria
Inclusion Criteria
- Subject's written informed consent obtained prior to any study-related procedure;
- Able to understand the study procedures, the risks involved and ability to be trained to use correctly the inhalers and to generate sufficient Peak Inspiratory Flow (PIF), using the In-Check device and Placebo inhaler;
- Male subjects aged 30 to 55 years inclusive;
- Body mass index (BMI) within the range of 18 to 35 kg/m^2 inclusive;
- Non- or ex-smoker who smoked 1 year prior to screening;
- Good physical and mental status;
- Vital signs at screening within limits;
- 12-lead digitised Electrocardiogram (12-lead ECG) in triplicate considered as normal;
- Lung function measurements within normal limits at screening;
- Regular bowel movements at screening;
- Males with non-pregnant Women of Childbearing Potential (WOCBP) partners: they and/or their partner of childbearing potential must be willing to use a highly effective birth control method in addition to the male condom from the signature of the informed consent and until 90 days after the follow-up visit. Males with pregnant WOCBP partner: they must be willing to use male contraception (condom) from the signature of the informed consent and until 90 days after the follow-up visit.
Exclusion Criteria
- Participation in another clinical trial with an investigational drug in the 3 months or 5 half-lives of that investigational drug (whichever is longer) preceding the administration of the study drug;
- Clinically relevant and uncontrolled respiratory, cardiac, hepatic (including Gilbert syndrome), gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric disorder;
- Clinically relevant abnormal laboratory values;
- Subjects with history of breathing problems;
- Positive to Human Immunodeficiency Virus 1/Human Immunodeficiency Virus 2 (HIV1/HIV2) serology at screening;
- Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C at screening;
- Blood donation or blood loss (equal or more than 450 mL) less than 2 months prior screening or prior to treatment;
- Positive urine test for cotinine;
- Documented history of alcohol abuse within 12 months prior to screening or a positive alcohol breath test;
- Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen;
- Intake of non-permitted concomitant medications in the predefined period;
- Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or before treatment;
- Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation used in the trial;
- Unsuitable veins for repeated venipuncture;
- Heavy caffeine drinker;
- Abnormal haemoglobin level at screening;
- Subjects using e-cigarettes within 6 months prior to screening;
- Subjects been involved in a study involving a 14^C-labeled drug within the 12 months prior to enrollment;
- Subjects with exposure to significant diagnostic or therapeutic radiation or current employment in a job requiring radiation exposure monitoring within 12 months prior to Day-1;
- Documented coronavirus disease 2019 (COVID-19) diagnosis within the last 8 weeks or which has not resolved within 14 days prior to screening and before treatment.
Data sourced from ClinicalTrials.gov (NCT04756960). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.